ArticleViruses2021
Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19.
Open access · goldAbstract read
In one paragraph
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- A Meta-Analysis of the Impact of Using Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) on Mortality, Severity, and Healthcare Resource Utilization in Patients with COVID-19.Advances in respiratory medicine · 2025Pooled it
- Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality.Journal of clinical epidemiology · 2021Pooled it
- Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.Frontiers in immunology · 2023Trial
- Therapeutic Targeting of the Bradykinin B2 Receptor in Immunological and Vascular Diseases: Insights from Kinin Biology to Clinical Outcomes.Clinical reviews in allergy & immunology · 2026Review
- Therapeutic Potential of C1-Inhibitor in Vascular Diseases and Beyond.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Eosinophilic inflammation in hereditary angioedema: a single-center real-world retrospective chart review study.Frontiers in immunology · 2026Article
- Assessment of the myocardial effects of Bradykinin inhibitors by cardiac magnetic resonance (CMR) in discharged COVID-19 patients.Scientific reports · 2025Article
- Patterns of C1-Inhibitor Plasma Levels and Kinin-Kallikrein System Activation in Relation to COVID-19 Severity.Life (Basel, Switzerland) · 2024Article
- Angiotensin receptor blockers could be superior to angiotensin-converting enzyme inhibitors in COVID-19 management: the potential role of bradykinin.Irish journal of medical science · 2024Article
- Emerging role of complement in COVID-19 and other respiratory virus diseases.Cellular and molecular life sciences : CMLS · 2024Review
- Potential Pathways and Pathophysiological Implications of Viral Infection-Driven Activation of Kallikrein-Kinin System (KKS).Viruses · 2024Review
- Angiopoietin2 is associated with coagulation activation and tissue factor expression in extracellular vesicles in COVID-19.Frontiers in medicine · 2024Article
- Inhibition of bradykinin in SARS-CoV-2 infection: a randomised, double-blind trial of icatibant compared with placebo (ICASARS).BMJ open · 2023Article
- Podoplanin and CLEC-2 levels in patients with COVID-19.Research and practice in thrombosis and haemostasis · 2023Article
- Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance.Journal of inflammation (London, England) · 2023Review
- Function and structure of bradykinin receptor 2 for drug discovery.Acta pharmacologica Sinica · 2023Review
- Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment.Clinical drug investigation · 2023Review
- Association of Ang/Tie2 pathway mediators with endothelial barrier integrity and disease severity in COVID-19.Frontiers in physiology · 2023Article
- Vascular risk factors for COVID-19 ARDS: endothelium, contact-kinin system.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 1 country.
Eli MansourDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.ORCID 0000-0001-6450-6930
Andre C PalmaDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.ORCID 0000-0001-6823-0847
Raisa G UlafDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.ORCID 0000-0003-0013-2831
Luciana C RibeiroDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.
Ana Flavia BernardesDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.
Thyago A NunesDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.ORCID 0000-0003-0202-0550
Marcus V AgrelaDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.
Bruna BombassaroObesity and Comorbidities Research Center, University of Campinas, 13083-864 Campinas, São Paulo, Brazil.
Milena Monfort-PiresObesity and Comorbidities Research Center, University of Campinas, 13083-864 Campinas, São Paulo, Brazil.
Rafael L CamargoObesity and Comorbidities Research Center, University of Campinas, 13083-864 Campinas, São Paulo, Brazil.
Eliana P AraujoObesity and Comorbidities Research Center, University of Campinas, 13083-864 Campinas, São Paulo, Brazil.
Natalia S BrunettiAutoimmune Research Lab, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, 13083-862 Campinas, São Paulo, Brazil.ORCID 0000-0003-2803-3763
Alessandro S FariasAutoimmune Research Lab, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, 13083-862 Campinas, São Paulo, Brazil.
Antônio Luís E FalcãoDepartment of Surgery, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.
Thiago Martins SantosDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.
Plinio TrabassoDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.
Rachel P DertkigilDepartment of Radiology, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.
Sergio S DertkigilDepartment of Radiology, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.ORCID 0000-0002-3694-9539
Maria Luiza MorettiDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.ORCID 0000-0002-2280-5649
Licio A VellosoDepartment of Internal Medicine, School of Medical Sciences, University of Campinas, 13083-887 Campinas, São Paulo, Brazil.
Universidade Estadual de Campinas (UNICAMP) · BR
Funding
Fundação de Amparo à Pesquisa do Estado de São Paulo 2013/07607
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19 Drug TreatmentAdultAgedBradykininCase-Control StudiesComplement C1 Inhibitor ProteinDrug RepositioningFemaleHumansKallikrein-Kinin SystemKallikreinsLungMaleMiddle AgedBradykininComplement C1 Inhibitor ProteinicatibantKallikreinsangiotensin converting enzyme 2bradykinincoronavirusinflammationlung
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.